✦ LIBER ✦

Gemcitabine (G) followed by 2nd line Docetaxel (D) is feasible in advanced NSCLC: Results from a randomized phase II study

✍ Scribed by Manegold, C; Pitz, L; Koschel, G; Schott, K; Waletzko, E; Hruska, D; Dornoff, W; Gosse, H; Gatzemeier, U

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Docetaxel/gemcitabine or cisplatin/gemci

✍ D. Binder; H. Schweisfurth; C. Grah; C. Schäper; B. Temmesfeld-Wollbrück; G. Sie 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 340 KB

P-463 Preliminary results of a multicent

✍ Bernardini, I.; Rinaldi, M.; Crinò, L.; Nardi, M.; De Marinis, F.; Tonato, M.; S 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 130 KB

A phase II study of docetaxel (D) and ge

✍ Agelaki, S.; Papadakis, E.; Tsiafaki, X.; Rapti, A.; Toubis, M.; Bania, E.; Kalb 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 158 KB

P-531 Phase II study of sequential gemci

✍ Chiappori, Alberto; Simon, George; Lima, Caio Rocha; Williams, Charles; Haura, E 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 360 KB

1307 POSTER First-line chemotherapy with

✍ C. Tibaldi; E. Vasile; M. Lo Dico; A. Antonuzzo; R. Di Marsico; G. Tartarelli; A 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 60 KB

P-457 Docetaxel/gemcitabine vs. cisplati

✍ Binder, D.; Schweisfurth, H.; Grah, C.; Schäper, C.; Temmesfeld-Wollbrück, B.; S 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 276 KB